CLEVELAND, Ohio— Cleveland-based biotechnology company Discovery Therapeutics Caribe will soon be studying a treatment for diabetic ulcers that was developed in Cuba.
are applied directly to the surface of wounds. However, Heberprot-P is an injection that delivers the active ingredient under the skin, past the chronic wound environment that can otherwise degrade the drug and reduce the effectiveness of the treatment.epidermal growth factor plays a crucial role in the body’s healing process.
Nearly half of patients who undergo lower extremity amputation resulting from diabetic foot ulcers do not survive beyond five years.
Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite: